Fine-tuning the native immune system

Transforming Cancer Therapy Through Immune Reprogramming

Abbmira Therapeutics AG is revolutionizing cancer treatment. We develop first-in-class immunomodulatory drugs designed to reprogram the native immune system—specifically tumor-associated macrophages (TAMs)—to deliver robust and durable anticancer responses. Our lead candidate, Compound42, holds the promise of reshaping the tumor microenvironment to promote immune-driven tumor regression and improve patient outcomes.

Background

Cancer kills 1 in 10 people globally. Many tumors evade existing therapies by exploiting tumor-associated macrophages (TAMs), which can switch to an immune-suppressive state that shields tumors from attack. This leads to drug resistance and low response rates for existing therapies. Patients urgently need new drugs that reactivate their native immune system to overcome tumor-driven evasion and improve survival.

Technology

Abbmira’s small-molecule Compound42 reprograms macrophages from a pro-tumor to an anti-tumor state, driving an effective immune response against cancer. By targeting a specific immune pathway with our drugs, we overcome the limitations of existing therapies. Our first-in-class immunomodulator aims to enhance treatment effectiveness, offering new hope to patients with hard-to-treat cancers.